Opendata, web and dolomites


Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure (AHF) condition.

Total Cost €


EC-Contrib. €






Project "Doraya" data sheet

The following table provides information about the project.


Organization address
postcode: 4250407
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REVAMP MEDICAL LTD IL (NETANIA) coordinator 50˙000.00


 Project objective

Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between 20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3 decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics. The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients, including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant to diuretics, this represents a huge unmet market that Doraya can service.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DORAYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DORAYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HUD (2018)


Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More